Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole
Oral Squamous Cell Carcinoma (OSCC) presents an important challenge for the health systems worldwide. Thus, unraveling the biological mechanisms involved in OSCC pathogenesis is essential to the discovery of new drugs with anticancer potential. The Hedgehog (HH) pathway has shown promising results a...
Main Authors: | Raíza Dias Freitas, Rosane Borges Dias, Manuela Torres Andion Vidal, Ludmila de Faro Valverde, Rafaela Gomes Alves Costa, Andresa Karen Andrade Damasceno, Caroline Brandi Schlaepfer Sales, Leonardo de Oliveira Siquara da Rocha, Mitermayer Galvão dos Reis, Milena Botelho Pereira Soares, Ricardo Della Coletta, Thiago Almeida Pereira, Daniel Pereira Bezerra, Clarissa Araújo Gurgel Rocha |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.563838/full |
Similar Items
-
Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
by: Silpa Gampala, et al.
Published: (2021-06-01) -
Vismodegib: The first drug approved for advanced and metastatic basal cell carcinoma
by: A K Dubey, et al.
Published: (2013-01-01) -
Medical marijuana for the treatment of vismodegib-related muscle spasm
by: Joyce T. Yuan, MD, et al.
Published: (2017-09-01) -
Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
by: Suruchi Aditya, et al.
Published: (2013-01-01) -
Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
by: Jayson Miedema, MD, et al.
Published: (2018-01-01)